New journal coming to touchIMMUNOLOGY soon!
Share this Article
Related Content In Rheumatic Diseases
An Update on Biosimilars in Rheumatic and Musculoskeletal Disorders
touchREVIEWS in RMD. 2023;2(1):46–49 DOI: https://doi.org/10.17925/RMD.2023.2.1.46
Biologics are medications derived from biological sources used to treat several immune-mediated inflammatory diseases. These medications interfere with autoimmune processes by inhibiting specific molecular or cellular targets. They are highly effective medications, mostly used in cases of moderate-to-severe disease activity. As such, biologics have revolutionized the treatment of and transformed outcomes for patients with rheumatological […]
Health Equity in Rheumatology: A Global Health Perspective
touchREVIEWS in RMD. 2023;2(1):42–45 DOI: https://doi.org/10.17925/RMD.2023.2.1.42
The preamble of the World Health Organization’s constitution defines health as “a state of complete physical, mental and social wellbeing, and not merely the absence of disease or infirmity”.1 An optimal state of health is considered a fundamental human right. When each human has the ability and opportunity to attain optimal health, only then can a […]
Challenges in Family Planning and Pregnancy for Women with Rheumatic Diseases
touchREVIEWS in RMD. 2023;2(1):28–36 DOI: https://doi.org/10.17925/RMD.2023.2.1.28
Systemic rheumatic diseases (RDs) commonly arise during a woman’s reproductive years and may have implications for family planning and pregnancy. Among the RDs, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are classically associated with an increased risk of adverse pregnancy outcomes (APOs), including miscarriage, foetal loss, preeclampsia, intrauterine growth restriction (IUGR) and preterm delivery.1–4 Although SLE pregnancy outcomes have improved over time, maternal mortality remains higher in women […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!